Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HP 13C Pyruvate MRI as a Response Monitoring Tool in High-Risk Prostate Cancer
NCT06384222Phase 2Active, not recruiting
- Start
- Dec 2024
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of [1-13C]pyruvate in prostate cancer (PCa). Started Dec 2024; status: active, not recruiting.
02
Drugs
[1-13C]pyruvate
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06384222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06384222.